Anaplastic giant cell thyroid carcinoma

Scandinavian Journal of Surgery

Volumn 93, Issue 4, 2004, Pages 272-277

  Wallin, Göran ^a   Lundell, G ^a   Tennvall, J ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Anaplastic thyroid cancer; Doxorubicin; Radiotherapy; Surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; COMBRETASTATIN; CYTOSTATIC AGENT; DOXORUBICIN; SODIUM IODIDE SYMPORTER;

ADULT; AGED; ANAPLASTIC CARCINOMA; ASPIRATION BIOPSY; CANCER PATIENT; CANCER SURVIVAL; CYTOTOXICITY; FEMALE; GENE THERAPY; GIANT CELL CARCINOMA; GROWTH INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; THYROID CARCINOMA; TUMOR GROWTH;

EID: 11844262036     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749690409300404     Document Type: Review

References (52)

1. Aldinger KA, Saaman NA, Ibanez M, Hill CS Jr: Anaplastic carcinoma of the thyroid: A review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978;41:2267
2. Tan RK, Finley RK, Driscoll D, Bakamjian V, Hicks WL, Shedd DP: Anaplastic carcinoma of the thyroid: A 24 -year experience. Head Neck 1995;17:41-47
3. Ain KB Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;9:715-726
4. Jereb B, Stjernswärd J, Löwhagen T: Anaplastic giant-cell carcinoma of the thyroid: a study of treatment and prognosis. Cancer 1975;35:1293-1295
5. Akslen LA, Haldorsen T, Thoresen S, Glattre E: Incidence of thyroid cancer in Norway 1970-1985. APMIS 1990;98:549-558
6. Mazzaferri EL: Undifferentiated thyroid carcinoma and unusal thyroid malignancies. In: Mazzaferri EL, Samaan NA, (Eds): Endocrine tumors. Boston: Blackwell Scientific Publications, 1993;98:378-398
7. Demeter JG, De Jong SA, Lawrence AM Paloyan E: Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991;100:956-961
8. Junor EJ, Paul J, Nicholas SR: Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18:83-88
9. Nel CJ, van Heerden JA, Goellner JR, Gharib H, McConahey WM, Taylor WF, Grant CS: Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases: Mayo Clin Proc 1985;60:51-58
10. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, Grimelius L, Lundell G, Wallin G: Anaplastic giant cell carcinoma of the thyroid gland-treatment and survival during 25 years. World J Surg 1998;22:725-730
11. Tennvall J, Lundell G, Hallquist A, et al: Combined doxorubicin, hyperfractionated radiotherapy and surgery in anaplastic thyroid carcinoma. Report on two protocols. Cancer 1994;74:1348-1354
12. Tallroth E, Wallin G, Lundell G, Löwhagen T, Einhorn J: Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 1987;60:1428-1431
13. Ekman E, Lundell G, Tennvall J, Wallin G: Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am 1990;23:523-527
14. Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG, Redmond HP: Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003;4:760-768
15. Löwhagen T, Willems JS, Lundell G, Sundblad R, Granberg PO: Aspiration biopsy cytology in diagnosis of thyroid cancer. World J Surg 1981;5:61-73
16. Akerman M, Tennvall J, Biörklund A, Mårtensson H, Möller T: Sensitivity and specificity of fine needle aspiration cytology in the diagnosis of tumors of the thyroid gland. Acta Cytol 1985;29:850-855
17. Tennvall J, Cavallin-Ståhl E, Akerman M: Primary localized non-Hodgkin's lymphoma of the thyroid: a retrospective clinicopathological review. Eur J Surg Oncol 1987;13:297-307
18. Loré JM Jr: Surgery for advanced thyroid malignancy. Otolaryngol Clin North Am 1991;24:1295-1319
19. Levendag PC, DePorre PMZR, van Putten WLJ: Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 1993;26:125-128
20. Hötling T, Meyerbier H, Buhr H: Stellenwert der tracheotomie in der behandlung des respiratorischen notfalls beim anaplastischen schilddrusenkarzinom. Wien Klin Wochenschr 1990;102:264-266
21. Thames HD, Peters LJ, Rodney WH, Fletcher GH: Accelerated fractionation vs hyperfractionation: Rationales for several treatments per day. Int J Radiat Oncol Biol Phys 1982;9:127-138
22. Withers HR: Biologic basis for altered fractionation schemes. Cancer 1985;55:2086-2095
23. Venkatesh YSS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA: Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321-330
24. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP: Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991;67:564-566
25. Wendt TG, Chucholowski M, Hartensein R, Rohloff R, Willich N: Sequential chemo-radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1985;12:397-399
26. Wallgren A, Norin T: Combined chemotherapy and radiation therapy in spindle and giant cell carcinoma of the thyroid gland. Report of a case. Acta Radiol Ther Phys Biol. 1973;12:17-20
27. Rogers JD, Lindberg RD, Hill CS Jr, Gehan EG: Spindle and giant cell carcinoma of the thyroid: A different therapeutic approach. Cancer 1974;34:1328-1332
28. Simpson WJ: Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980;23:25-27
29. Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy. A new approach. Cancer 1983;52:954-957
30. Kim JH, Leeper RD: Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-2375
31. Andersson T, Biörklund A, Landberg T, Åkerman M, Aspegren K, Ingemansson S: Combined therapy for undifferentiated giant and spindle cell carcinoma of the thyroid. Acta Otolaryngol. 1977;83:372-377
32. Tennvall J, Andersson T, Biörklund A, Ingemansson S, Landberg T, Akerman M: Undifferentiated giant and spindle cell carcinoma of the thyroid. Report on two combined treatment modalities. Acta Radiol Oncol 1979;18:408-416
33. Werner B, Abele J, Alveryd A, Biörklund A, Franzén S, Granberg PO, Landberg T, Lundell G, Löwhagen T, Sundblad R, Tennvall J: Multimodal therapy in anaplastic giant cell thyroid carcinoma. World J Surg 1984;8:64-70
34. Byfield JE, Lynch M, Kulhanian F, Chan PYM: Cellular efffects of combined Adriamycin and X- irradiation in human tumor cells. Int J Cancer 1977;19:194-204
35. Rosenthal CJ, Rotman M: The Development of chemotherapy drugs as radiosensitizers: an Overview. In: Rotman M, Rosenthal CJ (Eds): Concomitant Continous Infusion and Radiation. Berlin: Springer Verlag, pp1-9, 1991
36. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Åkerman M, Hjelm-Skog A-L, Wallin G: Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002;86:1848-1853
37. Dische S, Saunders MI: Continous, hyperfractionated, accelerated radiotherapy (CHART). An interim report upon late morbidity. Radiother. Oncol. 1989;6:65-72
38. Wong CS, Van Dyk J, Simpson J: Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991;20:3-9
39. Mitchell G, Huddart R, Harmer C: Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1999;1:33-38
40. Asakawa H, Kobayashi T, Komoike Y, Maruyama H, Nakano Y, Tamaka Y et al: Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcionoma. Anticancer Res 1997;17:2757-2762
41. Satake S, Sugawara I, Watanabe M, Takami H: Lack of point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett 1997;116:33-39
42. Ain KB, Tofiq S, Taylor KD: Antineoplastic activity of Taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 1996;81:3650-3653
43. Ain KB, Egorin MJ, DeSimone PA: Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587-594.
44. Hama Y, Shimzu T, Hosaka S, Sugenoya A, Usuda N: Therapeutic efficacy of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillo (TNP-470;AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Exp Toxicol Pathol 1997;49:239-247
45. Antiangiogenesis drugs target cancers, mechanisms. News. JNCI 2000;92:520-522
46. Dziba JM, Marcinek R, Venkataraman GM, Robinson JA, Ain KB: Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002;12:1063-1070
47. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000;407:249-257
48. Wynford-Thomas D: Molecular basis of epithelial tumorgenesis: the thyroid model. Crit Rev Oncog 1993;4:1-23
49. Dobashi Y, Sugimura H, Sakamoto A, Mernyei M, Mori M, Oyama T, Machinami R: Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 1994;3:9-14
50. - symporter gene methylation status. J Clin Endocrinol Metab 1999;84:2449-2457
51. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC: The sodium iodide symporter and its potential in cancer therapy. J Clin Endocrinol Metab 2001;86:3327-3335
52. --symporter gene. Endocrinology 1997;138:4493-4496